AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29885752 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 469
Study 29885752 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral health education
Number of subjects: 469
Study 28088925 — intervention group
Group type: EXPERIMENTAL
Intervention: Kundalini yoga (KY) intervention
Number of subjects: 81
Study 28088925 — intervention group
Group type: COMPARATOR
Intervention: Memory enhancement training (MET; gold-standard, active control)
Number of subjects: 81
Study 25698407 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (21,210 men)
Number of subjects: 42376
Study 25698407 — intervention group
Group type: COMPARATOR
Intervention: Control arm (21,166 men)
Number of subjects: 42376
Study 25698407 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 42376
Study 25698407 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 42376
Study 23650800 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) intervention applied to bilateral Xuehai (SP 10), Zusanli (ST36), Taichong (LR3), and Sanyinjiao (SP 6) for 30 min, once daily for 15 days.
Number of subjects: 30
Study 23650800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive endurance exercise (Harvard step test) for 30 min, once daily for 15 days.
Number of subjects: 30
Study 23650800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 30
Study 21091250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactotripeptides (3 mg of Ile‐Pro‐Pro/Val‐Pro‐Pro)
Number of subjects: 55
Study 21091250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactotripeptides
Number of subjects: 55
Study 18209670 — intervention group
Group type: EXPERIMENTAL
Intervention: OTZ (oxothiazolidine‐4‐carboxylic acid) 210 mg/kg per day every 8 hrs for 14 days
Number of subjects: 215
Study 18209670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 18209670 — intervention group
Group type: EXPERIMENTAL
Intervention: OTZ (oxothiazolidine‐4‐carboxylic acid)
Number of subjects: 215
Study 16599263 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 5 g daily for 6 weeks)
Number of subjects: 20
Study 16599263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15128893 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin (100 mg/m² IV on days 1, 22, and 43) plus radiotherapy (60 to 66 Gy in 30 to 33 fractions over 6 to 6.6 weeks)
Number of subjects: 459
Study 15128893 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (60 to 66 Gy in 30 to 33 fractions over 6 to 6.6 weeks)
Number of subjects: 459
Study 15128893 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin plus radiotherapy
Number of subjects: 459
Study 15128893 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 459
Study 11844177 — intervention group
Group type: EXPERIMENTAL
Intervention: Infoson (air-filled albumin microspheres)
Number of subjects: 23
Study 11844177 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 23
Study 11844177 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (Iopamiron 370)
Number of subjects: 23
Study 9566993 — intervention group
Group type: EXPERIMENTAL
Intervention: Food cooked in iron pots
Number of subjects: 45
Study 9566993 — intervention group
Group type: COMPARATOR
Intervention: Food cooked in aluminum pots
Number of subjects: 45
Study 8065733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentary injection of slow-release methylprednisolone (Depomedrol)
Number of subjects: 0
Study 8065733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8065733 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (Mepivacaine)
Number of subjects: 0
Study 3418088 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) enemas (2 g in 100 ml)
Number of subjects: 39
Study 3418088 — intervention group
Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (5-ASA) suppositories (1 g b.i.d.)
Number of subjects: 39
Study 31743564 — intervention group
Group type: EXPERIMENTAL
Intervention: TTC web-based self-management program
Number of subjects: 42
Study 31743564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to TTC program)
Number of subjects: 42
Study 30316496 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE) prior to Cognitive Bias Modification for Interpretation (CBM-I)
Number of subjects: 111
Study 30316496 — intervention group
Group type: COMPARATOR
Intervention: Relaxation prior to Cognitive Bias Modification for Interpretation (CBM-I)
Number of subjects: 111
Study 30316496 — intervention group
Group type: COMPARATOR
Intervention: Neutral Thinking prior to Cognitive Bias Modification for Interpretation (CBM-I)
Number of subjects: 111
Study 28557376 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered implants
Number of subjects: 40
Study 28557376 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical implants
Number of subjects: 40
Study 28557376 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tapered and cylindrical implants
Number of subjects: 40
Study 24433518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Transition to Parenthood Program (4-week duration)
Number of subjects: 33
Study 24433518 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 33
Study 23283675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial tubercle osteotomy (TTO)
Number of subjects: 81
Study 23283675 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps snip (QS)
Number of subjects: 81
Study 23283675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 22088886 — intervention group
Group type: EXPERIMENTAL
Intervention: Male neonates
Number of subjects: 131
Study 22088886 — intervention group
Group type: COMPARATOR
Intervention: Female neonates
Number of subjects: 131
Study 18665689 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training‐‐The Oregon Model (PMTO)
Number of subjects: 112
Study 18665689 — intervention group
Group type: COMPARATOR
Intervention: Regular services comparison group
Number of subjects: 112
Study 16448992 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitters)
Number of subjects: 240
Study 16448992 — intervention group
Group type: COMPARATOR
Intervention: Sustained smoking (sustained smokers)
Number of subjects: 240
Study 12595499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 7674
Study 12595499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7674
Study 11432177 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior technique of inferior alveolar nerve block
Number of subjects: 100
Study 11432177 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique of inferior alveolar nerve block
Number of subjects: 100
Study 9438598 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-Gy radiotherapy and 4 weeks 5-FU treatment
Number of subjects: 218
Study 9438598 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 218
Study 7512469 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR 240mg daily
Number of subjects: 931
Study 7512469 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20mg daily
Number of subjects: 931
Study 7512469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Verapamil + Enalapril or Hydrochlorothiazide)
Number of subjects: 931
Study 7512469 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 931
Study 3520382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO) - 20 consecutive daily treatments of 100% O2 followed by 7 booster treatments over 6 months
Number of subjects: 82
Study 3520382 — intervention group
Group type: COMPARATOR
Intervention: Control group - received 'air' (12.5% O2 at 1.75 atmospheres absolute)
Number of subjects: 82
Study 29568976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone 0.8 mg
Number of subjects: 12
Study 29568976 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular naloxone 0.8 mg
Number of subjects: 12
Study 29568976 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat pain threshold
Number of subjects: 12
Study 27879642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus curcumin and Boswellia serrata (curcumin/BSE group)
Number of subjects: 47
Study 27879642 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet alone (MD group)
Number of subjects: 47
Study 27879642 — intervention group
Group type: COMPARATOR
Intervention: Comparison between curcumin/BSE group and MD group
Number of subjects: 47
Study 24270165 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (5 trials/day over 3 days)
Number of subjects: 40
Study 24270165 — intervention group
Group type: COMPARATOR
Intervention: Massed training (15 trials in 1 session)
Number of subjects: 40
Study 24270165 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 21756847 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα2a 180 μg/wk plus daily Rbv 800-1200 mg
Number of subjects: 431
Study 21756847 — intervention group
Group type: COMPARATOR
Intervention: PegIFNα2b 1.5 μg/kg/week plus daily Rbv 800-1200 mg
Number of subjects: 431
Study 20735515 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 500 mg of azithromycin per day (3 days)
Number of subjects: 29
Study 20735515 — intervention group
Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 29
Study 19014165 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone
Number of subjects: 48
Study 19014165 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-tricalcium phosphate
Number of subjects: 48
Study 19014165 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-tricalcium phosphate composite graft (with 10% to 20% autogenous bone)
Number of subjects: 48
Study 19014165 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone
Number of subjects: 48
Study 15851525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy
Number of subjects: 161
Study 15851525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus cyclophosphamide (R+CTX)
Number of subjects: 161
Study 15851525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus methotrexate (R+MTX)
Number of subjects: 161
Study 15851525 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (MTX)
Number of subjects: 161
Study 12830040 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal warm blood cardioplegia
Number of subjects: 103
Study 12830040 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hyperkalemic cold blood cardioplegia and topical cardiac cooling (Control)
Number of subjects: 103
Study 10806608 — intervention group
Group type: EXPERIMENTAL
Intervention: tolbutamide 500 mg plus tolcapone 200 mg
Number of subjects: 12
Study 10806608 — intervention group
Group type: COMPARATOR
Intervention: tolbutamide 500 mg plus placebo
Number of subjects: 12
Study 8660076 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentration in cystic fibrosis group
Number of subjects: 31
Study 8660076 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiograph Northern score
Number of subjects: 31
Study 8660076 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma copper
Number of subjects: 31
Study 8660076 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma gamma‐glutamyltransferase
Number of subjects: 31
Study 8660076 — intervention group
Group type: COMPARATOR
Intervention: Traditional indices of inflammation
Number of subjects: 31
Study 2064999 — intervention group
Group type: EXPERIMENTAL
Intervention: Skicon Hygrometer
Number of subjects: 0
Study 2064999 — intervention group
Group type: EXPERIMENTAL
Intervention: CM420a
Number of subjects: 0
Study 2064999 — intervention group
Group type: EXPERIMENTAL
Intervention: CM420b
Number of subjects: 0
Study 2064999 — intervention group
Group type: EXPERIMENTAL
Intervention: CM820
Number of subjects: 0
Study 2064999 — intervention group
Group type: COMPARATOR
Intervention: Corneometers (CM420a, CM420b, CM820)
Number of subjects: 0
Study 6635871 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg
Number of subjects: 7
Study 6635871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31971139 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of private health providers and community sensitization on effective prompt care seeking and referral
Number of subjects: 10809
Study 31553517 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I hypertension
Number of subjects: 196
Study 31553517 — intervention group
Group type: COMPARATOR
Intervention: Prehypertension
Number of subjects: 196
Study 29504812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide single-use pen (SUP)
Number of subjects: 48
Study 29504812 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec FlexTouch®
Number of subjects: 48
Study 26843473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release hGH (SR-hGH) 2-mg injections weekly for 3 months
Number of subjects: 33
Study 26843473 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 33
Study 24014349 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent movie clips
Number of subjects: 209
Study 24014349 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent movie clips
Number of subjects: 209
Study 24014349 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exposure to media violence
Number of subjects: 209
Study 24014349 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of real-life violence exposure
Number of subjects: 209
Study 22344045 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training (30 Hz, ±1‐2 mm, 3 times per week)
Number of subjects: 24
Study 22344045 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 24
Study 22344045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) training (identical training without vibration)
Number of subjects: 24
Study 21126667 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (10 mg)
Number of subjects: 100
Study 21126667 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (10 mg) with morphine (100 mcg)
Number of subjects: 100
Study 21126667 — intervention group
Group type: COMPARATOR
Intervention: Isobaric bupivacaine (10 mg)
Number of subjects: 100
Study 21126667 — intervention group
Group type: COMPARATOR
Intervention: Isobaric bupivacaine (10 mg) with morphine (100 mcg)
Number of subjects: 100
Study 17437725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 533
Study 17437725 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 533
Study 16281214 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Eclectic Psychotherapy (BEP)
Number of subjects: 24
Study 16281214 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 24
Study 11955901 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon5 (sodium hyaluronate 2.3%)
Number of subjects: 99
Study 11955901 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon (sodium hyaluronate 1%)
Number of subjects: 99
Study 11955901 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon GV (sodium hyaluronate 1.4%)
Number of subjects: 99
Study 11955901 — intervention group
Group type: COMPARATOR
Intervention: Control group (Healon in 1 eye and Healon GV in the fellow eye)
Number of subjects: 99
Study 10678478 — intervention group
Group type: EXPERIMENTAL
Intervention: Drama-in-education programme
Number of subjects: 1080
Study 10678478 — intervention group
Group type: COMPARATOR
Intervention: Written information about HIV/AIDS
Number of subjects: 1080
Study 9202548 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA) with intravenous alfentanil, mean dose 1.03 mg
Number of subjects: 100
Study 9202548 — intervention group
Group type: COMPARATOR
Intervention: Control group with intravenous pethidine, mean dose 62.5 mg
Number of subjects: 100
Study 1527232 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine and valproic acid combination
Number of subjects: 1
Study 1527232 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine alone
Number of subjects: 1
Study 1527232 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid alone
Number of subjects: 1
Study 2862112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 2862112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 30952505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried plums (DP)
Number of subjects: 100
Study 30952505 — intervention group
Group type: COMPARATOR
Intervention: Refined carbohydrate-rich snack (low-fat muffins: LFM)
Number of subjects: 100
Study 30457892 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric-containing herbal combination tablets
Number of subjects: 30
Study 30457892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30457892 — intervention group
Group type: COMPARATOR
Intervention: Turmeric tablets
Number of subjects: 30
Study 27053525 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine
Number of subjects: 8
Study 27053525 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA
Number of subjects: 8
Study 27053525 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA
Number of subjects: 8
Study 27053525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 24989666 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg BID
Number of subjects: 540
Study 24989666 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg TID
Number of subjects: 540
Study 22301554 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 11
Study 22301554 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 11
Study 20826249 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells (BMCs) - 100 million intracoronary BMCs administered 3 to 10 days post-procedure
Number of subjects: 40
Study 20826249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17999989 — intervention group
Group type: EXPERIMENTAL
Intervention: PTGS2 polymorphisms (specifically Ex10 +837 T>C marker rs5275) in PLCO cohort
Number of subjects: 2321
Study 17999989 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analyses of PTGS2 variants in PLCO cohort
Number of subjects: 2321
Study 15781538 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperbaric intrathecal solution of 10 mg bupivacaine
Number of subjects: 150
Study 15781538 — intervention group
Group type: EXPERIMENTAL
Intervention: isobaric intrathecal solution of 10 mg bupivacaine
Number of subjects: 150
Study 15781538 — intervention group
Group type: EXPERIMENTAL
Intervention: hypobaric intrathecal solution of 10 mg bupivacaine
Number of subjects: 150
Study 12552188 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA-containing propofol (ECP) 2 mg/kg
Number of subjects: 40
Study 12552188 — intervention group
Group type: COMPARATOR
Intervention: Sulfite-containing propofol (SCP) 2 mg/kg
Number of subjects: 40
Study 10817176 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscope fitted with a transparent cap
Number of subjects: 50
Study 10817176 — intervention group
Group type: COMPARATOR
Intervention: Ordinary colonoscope without a cap
Number of subjects: 50
Study 8891643 — intervention group
Group type: EXPERIMENTAL
Intervention: gap paradigm
Number of subjects: 23
Study 8891643 — intervention group
Group type: COMPARATOR
Intervention: control group (elderly normal subjects)
Number of subjects: 23
Study 1905707 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (tegafur + MMC)
Number of subjects: 169
Study 1905707 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (UFT + MMC)
Number of subjects: 169
Study 29574438 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilisation and advocacy intervention (Sonke CHANGE) implemented over 18 months.
Number of subjects: 2600
Study 29574438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2600
Study 29574438 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilisation and advocacy intervention (Sonke CHANGE).
Number of subjects: 2600
Study 27261987 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based yoga intervention
Number of subjects: 0
Study 27261987 — intervention group
Group type: COMPARATOR
Intervention: Walking control condition
Number of subjects: 0
Study 24074719 — intervention group
Group type: EXPERIMENTAL
Intervention: NexoBrid™ (NXB) applied for 4 hours
Number of subjects: 0
Study 24074719 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) including surgical excisional or non-surgical debridement
Number of subjects: 0
Study 24074719 — intervention group
Group type: EXPERIMENTAL
Intervention: NexoBrid™ (NXB)
Number of subjects: 0
Study 24074719 — intervention group
Group type: COMPARATOR
Intervention: NexoBrid™ (NXB) and SOC
Number of subjects: 0
Study 22214181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue information condition
Number of subjects: 88
Study 22214181 — intervention group
Group type: COMPARATOR
Intervention: Control condition (generic sleep-related information)
Number of subjects: 88
Study 20464297 — intervention group
Group type: EXPERIMENTAL
Intervention: 70%WPI:30%MS (milk whey proteins and modified starch)
Number of subjects: 16
Study 20464297 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (control group)
Number of subjects: 16
Study 18406955 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 84
Study 18406955 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 84
Study 15620767 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction
Number of subjects: 128
Study 15620767 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful Coronectomy
Number of subjects: 128